Skip to content
Home
Charles Venuto, Pharm.D.

Charles Venuto, Pharm.D.

Contact

Office (585) 276-5622

About Me

Faculty Appointments

Associate Professor - Department of Neurology, Center for Health and Technology (SMD)

Credentials

Awards

American Foundation for Pharmaceutical Education Gateway to Research Scholar.

Dr. Daniel H. Murray Memorial Professional Development Award.

Kelli Jordan Memorial Clinical Research Award.

Young Investigator Award, 19th Conference on Retroviruses and Opportunistic Infections.

Research

Research Bio
Charles Venuto, PharmD, is a clinical pharmacologist with experience in pharmacokinetic and population pharmacokinetic modeling. His main research interests focus on characterizing the pharmacokinetics and pharmacodynamics of approved and investigational drugs and identifying influe...
Research Bio
Charles Venuto, PharmD, is a clinical pharmacologist with experience in pharmacokinetic and population pharmacokinetic modeling. His main research interests focus on characterizing the pharmacokinetics and pharmacodynamics of approved and investigational drugs and identifying influential sources of variability in drug behavior. These could include: pharmacogenetics, drug-drug interactions, and disease progression factors. Dr. Venuto has collaborated with the New York State Center of Excellence Translational Pharmacology Research Core, the AIDS Clinical Trials Group, and CHDI (formerly the Cure Huntington's Disease Initiative) in various clinical pharmacology modeling and simulation projects.

Awards and Honors
American Foundation for Pharmaceutical Education Gateway to Research Scholar (2007)
Dr. Daniel H. Murray Memorial Professional Development Award, University at Buffalo School of Pharmacy and Pharmaceutical Sciences (2010)
Kelli Jordan Memorial Clinical Research Award, University at Buffalo School of Pharmacy and Pharmaceutical Sciences (2010)
Young Investigator Award, 19th Conference on Retroviruses and Opportunistic Infections (2012)
Journal Articles
Kieburtz K, Venuto CS. TRACK-HD: both promise and disappointment. Lancet Neurology 2012; 11(1): 25-5. PMID: 22137355.

Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington Disease. Movement Disorders 2012; 27(1): 31-41. PMID: 21997232.

Ma Q, Zingman BS, Luque A, Fischl MA, Gripshover B, Venuto CS, DiFrancesco R, Forrest A, Morse GD. Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance related disorders. Therapeutic Drug Monitoring 2011; 33(3): 309-314. PMID: 21544014.

Goodman L Sia C, Carnes R, Vetter L, Taubman F, Venuto CS, McGarry A, Kieburtz K, Agarwal P. Advocacy recruiting for Huntington's Disease clinical trials. PLoS Currents 2011; 3: RRN1230. PMID: 21532913.

Venuto C, Brown J, Butler M, Dodds EA. Alternative therapies for Clostridium difficile infection. Pharmacotherapy 2010; 30(12): 1266-78. PMID: 21114394.

Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forest A, Morse GD. Multidrug Resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 2007; 8(3): 227-235. PMID: 17324111.

Education
Pharm.D., State University of New York at Buffalo, 2010
B.S. Molecular Biology and Microbiology, University of Central Florida, 2006

Publications

Journal Articles

Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease.

Bernal EA, Yang S, Herbst K, Venuto CS

Clinical and translational science.. 2024 November 17 (11):e70066. Epub 1900 01 01.

Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson's Disease.

Gonzalez-Latapi P, Gochanour C, Cho H, Ho Choi S, Caspell-Garcia C, Coffey C, Brumm M, Lafontant DE, Xiao Y, Tanner C, Venuto CS, Kieburtz K, Chahine LM, Poston KL, Siderowf A, Marek K, Simuni T

medRxiv : the preprint server for health sciences.. 2024 October 10 Epub 10/10/2024.

Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease.

Oertel WH, Müller HH, Unger MM, Schade-Brittinger C, Balthasar K, Articus K, Brinkman M, Venuto CS, Tracik F, Eberling J, Eggert KM, Kamp C, Kieburtz K, Boyd JT

NEJM evidence.. 2023 September 2 (9):EVIDoa2200311. Epub 08/22/2023.

Toward precision prescribing for methadone: Determinants of methadone deposition.

Talal AH, Ding Y, Venuto CS, Chakan LM, McLeod A, Dharia A, Morse GD, Brown LS, Markatou M, Kharasch ED

PloS one.. 2020 15 (4):e0231467. Epub 04/17/2020.

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.

Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, Wuest DM, Church BW, Khalil IG, Hayete B, Venuto CS

The Lancet. Neurology.. 2017 November 16 (11):908-916. Epub 09/25/2017.

Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s.

Gupta SK, Yeh E, Kitch DW, Brown TT, Venuto CS, Morse GD, Ha B, Melbourne K, McComsey GA

The Journal of antimicrobial chemotherapy.. 2017 July 172 (7):2042-2048. Epub 1900 01 01.

Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques.

Venuto CS, Markatou M, Woolwine-Cunningham Y, Furlage R, Ocque AJ, DiFrancesco R, Dumas EO, Wallace PK, Morse GD, Talal AH

Antimicrobial agents and chemotherapy.. 2017 May 61 (5)Epub 04/24/2017.

Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.

Venuto CS, Talal AH

Clinical pharmacology in drug development.. 2017 March 6 (2):169-175. Epub 1900 01 01.

Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.

Talal AH, Venuto CS, Younis I

Clinical pharmacology in drug development.. 2017 March 6 (2):206-212. Epub 1900 01 01.

Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Bednasz CJ, Venuto CS, Ma Q, Morse GD

Clinical pharmacology in drug development.. 2017 March 6 (2):135-139. Epub 1900 01 01.

A review of disease progression models of Parkinson's disease and applications in clinical trials.

Venuto CS, Potter NB, Ray Dorsey E, Kieburtz K

Movement disorders : official journal of the Movement Disorder Society.. 2016 July 31 (7):947-956. Epub 05/26/2016.

Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.

Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.. 2016 March 22 (3):287-97. Epub 1900 01 01.

Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.

Bednasz C, Luque AE, Zingman BS, Fischl MA, Gripshover BM, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q

Current vascular pharmacology.. 2016 14 (3):280-7. Epub 1900 01 01.

Recent advances in management of the HIV/HCV coinfected patient.

Bednasz CJ, Sawyer JR, Martinez A, Rose PG, Sithole SS, Hamilton HR, Kaufman FS, Venuto CS, Ma Q, Talal A, Morse GD

Future virology.. 2015 10 (8):981-997. Epub 1900 01 01.

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD

The Journal of antimicrobial chemotherapy.. 2014 December 69 (12):3300-10. Epub 08/25/2014.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC,

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.. 2014 February 58 (4):555-63. Epub 11/18/2013.

Pharmacologic approaches to the treatment of Huntington's disease.

Venuto CS, McGarry A, Ma Q, Kieburtz K

Movement disorders : official journal of the Movement Disorder Society.. 2012 January 27 (1):31-41. Epub 10/13/2011.

TRACK-HD: both promise and disappointment.

Kieburtz K, Venuto C

The Lancet. Neurology.. 2012 January 11 (1):24-5. Epub 12/02/2011.

Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

Ma Q, Zingman BS, Luque AE, Fischl MA, Gripshover BM, Venuto CS, DiFrancesco R, Forrest A, Morse GD

Therapeutic drug monitoring.. 2011 June 33 (3):309-14. Epub 1900 01 01.

Advocacy Recruiting for Huntington's Disease Clinical Trials.

Goodman L, Sia C, Carnes R, Vetter L, Taubman F, Venuto CS, McGarry A, Kieburtz K, Agarwal P

PLoS currents.. 2011 April 123 :RRN1230. Epub 04/12/2011.

Alternative therapies for Clostridium difficile infections.

Venuto C, Butler M, Ashley ED, Brown J

Pharmacotherapy.. 2010 December 30 (12):1266-78. Epub 1900 01 01.

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD

Pharmacogenomics.. 2007 March 8 (3):227-35. Epub 1900 01 01.